A review surveys senomorphic therapies that suppress harmful senescent cell signaling, maps SASP regulatory pathways, and highlights translational gaps for development.
Key Takeaways
- Even when less than 1% of all cells are senescent in a tissue
- There are also a great many senomorphic compounds
- There is not enough profit to be made to support the high costs of clinical trials